Beckman Coulter introduces antipsychotic drug testing to address unmet clinical need
Beckman Coulter, a global clinical diagnostics leader, will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.